Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | GAA | P10253 | 5/20 | 0.47 |
| ▸ | PKM | P14618 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5131355 | 0.94 | AVPR1A (0.46) | AVPR1AALDH1A1GAAPKMSMN1; SMN2 | |
| SCHEMBL5128250 | 0.88 | AVPR1A (0.45) | AVPR1AALDH1A1GAAPKMSMN1; SMN2 | |
| SCHEMBL5128879 | 0.88 | GAA (0.49) | AVPR1AALDH1A1GAAPKMSMN1; SMN2 | |
| SCHEMBL5131447 | 0.88 | PKM (0.46) | AVPR1AALDH1A1GAAPKMSMN1; SMN2 | |
| SCHEMBL5121390 | 0.88 | PKLR (0.49) | ALDH1A1GAAPKMSMN1; SMN2POLB | |
| SCHEMBL3828071 | 0.82 | EPHX2 (0.44) | ALDH1A1PKMSMN1; SMN2 | |
| SCHEMBL3808499 | 0.82 | EPHX2 (0.44) | AVPR1AALDH1A1GAAKMT2AMEN1 | |
| SCHEMBL5128076 | 0.81 | ATM (0.46) | ALDH1A1GAAPKMSMN1; SMN2POLB | |
| SCHEMBL5123851 | 0.80 | AVPR1A (0.46) | AVPR1AALDH1A1GAAPKMSMN1; SMN2 | |
| SCHEMBL5128193 | 0.79 | MEN1 (0.56) | ALDH1A1GAAPKMPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249128-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2008-10-09 | — | — | US | claimed |
| US-8580965-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-20080249128-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249128-A1 | Substituted Sulfonamide Compounds | BDKRB1, BDKRB2, NPSR1 | AVPR1A 23/4885ALDH1A1 2737/4885GAA 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.